Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy : A multi-database self-controlled case series study
Copyright: © 2024 Morciano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
BACKGROUND: Recently published studies have reported association of COVID-19 vaccine ChAdOx1-S (Vaxzevria) with Guillain Barré Syndrome (GBS). Less is known about the safety of other COVID-19 vaccines with respect to GBS outcome. This study investigated the association of COVID-19 vaccines with GBS in more than 15 million persons aged ≥12 years in Italy.
METHODS: Study population was all individuals aged ≥12 years who received at least one dose of COVID-19 vaccines, admitted to emergency care/hospital for GBS from 27 December 2020-30 September 2021 in Italy. Identification of GBS cases and receipt of at least one dose of mRNA-1273 (Elasomeran), BNT162b2 (Tozinameran), ChAdOx1-S (Vaxzevria) and Ad26.COV2.S (Janssen) through record linkage between regional health care and vaccination registries. Relative Incidence (RI) was estimated Self-controlled case series method adapted to event-dependent exposure using in the 42-day exposure risk period after each dose compared with other observation periods.
RESULTS: Increased risk of GBS was found after first (RI = 6.83; 95% CI 2.14-21.85) and second dose (RI = 7.41; 2.35-23.38) of mRNA-1273 and first dose of ChAdOx1-S (RI = 6.52; 2.88-14.77). Analysis by age found an increased risk among those aged≥60 years after first (RI = 8.03; 2.08-31.03) and second dose (RI = 7.71; 2.38-24.97) of mRNA-1273. The first dose of ChAdOx1-S was associated with GBS in those aged 40-59 (RI = 4.50; 1.37-14.79) and in those aged ≥ 60 years (RI = 6.84; 2.56-18.28).
CONCLUSIONS: mRNA-1273 and ChAdOx1-S vaccines were associated with an increased risk of GBS however this risk resulted in a small number of excess cases. Limitations were loss of GBS outpatient cases and imprecision of the estimates in the subgroup analysis due to a low number of events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
PloS one - 19(2024), 1 vom: 31., Seite e0290879 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morciano, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0290879 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367318016 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367318016 | ||
| 003 | DE-627 | ||
| 005 | 20240123232020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0290879 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM367318016 | ||
| 035 | |a (NLM)38241309 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morciano, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy |b A multi-database self-controlled case series study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2024 Morciano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
| 520 | |a BACKGROUND: Recently published studies have reported association of COVID-19 vaccine ChAdOx1-S (Vaxzevria) with Guillain Barré Syndrome (GBS). Less is known about the safety of other COVID-19 vaccines with respect to GBS outcome. This study investigated the association of COVID-19 vaccines with GBS in more than 15 million persons aged ≥12 years in Italy | ||
| 520 | |a METHODS: Study population was all individuals aged ≥12 years who received at least one dose of COVID-19 vaccines, admitted to emergency care/hospital for GBS from 27 December 2020-30 September 2021 in Italy. Identification of GBS cases and receipt of at least one dose of mRNA-1273 (Elasomeran), BNT162b2 (Tozinameran), ChAdOx1-S (Vaxzevria) and Ad26.COV2.S (Janssen) through record linkage between regional health care and vaccination registries. Relative Incidence (RI) was estimated Self-controlled case series method adapted to event-dependent exposure using in the 42-day exposure risk period after each dose compared with other observation periods | ||
| 520 | |a RESULTS: Increased risk of GBS was found after first (RI = 6.83; 95% CI 2.14-21.85) and second dose (RI = 7.41; 2.35-23.38) of mRNA-1273 and first dose of ChAdOx1-S (RI = 6.52; 2.88-14.77). Analysis by age found an increased risk among those aged≥60 years after first (RI = 8.03; 2.08-31.03) and second dose (RI = 7.71; 2.38-24.97) of mRNA-1273. The first dose of ChAdOx1-S was associated with GBS in those aged 40-59 (RI = 4.50; 1.37-14.79) and in those aged ≥ 60 years (RI = 6.84; 2.56-18.28) | ||
| 520 | |a CONCLUSIONS: mRNA-1273 and ChAdOx1-S vaccines were associated with an increased risk of GBS however this risk resulted in a small number of excess cases. Limitations were loss of GBS outpatient cases and imprecision of the estimates in the subgroup analysis due to a low number of events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a Ad26COVS1 |2 NLM | |
| 650 | 7 | |a JT2NS6183B |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Spila Alegiani, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Menniti Ippolito, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Belleudi, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Trifirò, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Zanoni, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Puccini, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Sapigni, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Mores, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Leoni, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Monaco, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Clagnan, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Zappetti, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bovo, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Cutillo, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Da Cas, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Massari, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 19(2024), 1 vom: 31., Seite e0290879 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:1 |g day:31 |g pages:e0290879 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0290879 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 1 |b 31 |h e0290879 | ||